PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell...
IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA)....
REJUVANT OUTPERFORMS ALL TESTED SUPPLEMENTS, INCLUDING STANDARD AKG AND NAD+ IN LANDMARK AGING CELL STUDY
FERNANDINA BEACH, Fla., May 28, 2026 /PRNewswire/ -- Ponce De Leon Health (PDLH), a commercial stage longevity company focused on the extension of healthspan and the reduction of biologic age in humans and animals, today highlighted the publication of a landmark peer-reviewed study in the scientific journal Aging Cell. Importantly, the study...
DA NANG GLOBAL BUSINESS SUMMIT 2026 – SILVER GENERATION INNOVATION EDITION
POSITIONING DA NANG AS SOUTHEAST ASIA'S INTERNATIONAL HUB FOR THE SILVER ECONOMY & MEDICAL TOURISM DA NANG, Vietnam, May 28, 2026 /PRNewswire/ -- The 3rd Da Nang Global Business Summit 2026, themed "Silver Generation Innovation", concluded successfully on May 15 at Pullman Danang Beach Resort, bringing together more than 120 delegates, including government leaders, healthcare experts, international investors, technology companies, real estate...
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
New collaboration combines Philips' global imaging expertise with ASCI's clinical leadership and regional network to strengthen education and clinical excellence across the region SINGAPORE, May 28, 2026 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration with the Asian Society of Cardiovascular Imaging (ASCI) to advance cardiovascular imaging education, clinical excellence and...
Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
SHANGHAI, May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical Device Regulation (EU MDR) certification on May 18, 2026, under the registered name "Calcium Hydroxylapatite (CaHA) Microsphere Injectable Facial Filler". Aphranel® is among the first regenerative CaHA injectable fillers from the Asia-Pacific region to achieve...
Scientific forum in Singapore explores advanced PET/CT imaging
SINGAPORE, May 28, 2026 /PRNewswire/ -- Singapore General Hospital (SGH), a leading academic medical centre in Singapore, on May 21 hosted "Advancing Precision Imaging with Next Generation PET/CT," a scientific forum that brought together experts in molecular imaging, nuclear medicine, radiology, cardiology, and translational research to discuss the clinical and research potential of advanced PET/CT imaging. The event...
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at...
Dymax Expands HLC Adhesive Portfolio with New Low Viscosity Medical Product
--New Adhesive Enables Reliable Bonding in Both Light and Shadowed Areas SINGAPORE, May 28, 2026 /PRNewswire/ -- Dymax, a global manufacturer of light-curing materials and equipment, today announced the release of HLC-M-1004, a low viscosity adhesive designed to support efficient assembly of complex medical devices. HLC‑M‑1004 expands the HLC™ Adhesives portfolio, which utilizes a hybrid light‑curable platform to support curing in...
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease...
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease...
